Research Article
Betatrophin Acts as a Diagnostic Biomarker in Type 2 Diabetes Mellitus and Is Negatively Associated with HDL-Cholesterol
Table 1
General characteristics of normal glucose participants and newly diagnosed T2DM patients.
| | Variables | NDM | T2DM | value |
| | Gender (male/) | 31/58 (53.4%) | 38/73 (52.1%) | 0.874 | | Age (years) | 39.43 ± 12.08 | 41.03 ± 9.74 | 0.404 | | BMI (kg/m2) | 26.80 ± 4.26 | 27.66 ± 3.39 | 0.204 | | WHR | 0.91 ± 0.07 | 0.93 ± 0.06 | 0.100 | | Betatrophin (pg/mL) | 407.41 (172.76–528.32) | 747.12 (544.26–1074.96) | <0.001 | | Fasting glucose (mM) | 5.51 ± 0.63 | 12.11 ± 3.89 | <0.001 | | Fast insulin (mIU/L) | 10.42 ± 5.83 | 15.10 ± 8.18 | <0.001 | | C peptide (g/L) | 1.65 ± 0.76 | 2.58 ± 2.97 | 0.021 | | HOMA-IR | 2.88 ± 1.98 | 7.90 ± 3.89 | <0.001 | | HOMA-% | 92.45 ± 46.83 | 44.77 ± 37.37 | <0.001 | | QUICKI | 0.34 ± 0.04 | 0.29 ± 0.02 | <0.001 | | TC (mM) | 4.89 ± 1.23 | 5.47 ± 1.15 | 0.007 | | TG (mM) | 1.29 (0.71–2.06) | 1.66 (1.09–2.35) | 0.213 | | LDL-C (mM) | 3.32 ± 0.92 | 3.42 ± 0.95 | 0.559 | | HDL-C (mM) | 1.50 ± 0.47 | 1.01 ± 0.37 | <0.001 | | Uric acid (mol/L) | 378.32 ± 110.26 | 335.40 ± 93.81 | 0.018 | | ALT (IU/L) | 21 (14–37.8) | 21 (14.5–31) | 0.308 | | AST (IU/L) | 24.28 ± 9.18 | 20.99 ± 12.48 | 0.096 |
|
|
BMI: body mass index; WHR: waist-to-hip ratio; FINS: fasting blood insulin; FBG: fasting blood glucose; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-%: homeostasis model assessment of cell function; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; QUICKI: Quantitative Insulin Sensitivity Check Index; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
.
|
